Showing 51-60 of 76 results for "".
Which Probiotic for Which Disease? Part 2
https://practicaldermatology.com/topics/atopic-dermatitis/which-probiotic-for-which-disease-part-2/23596/The conclusion of this 2-part series reviews the research for probiotics in the management of AD, acne, and psoriasis.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/23510/Pain-free Dermatology: Minimizing Discomfort in Procedures for Children and Adults
https://practicaldermatology.com/topics/general-topics/pain-free-dermatology-minimizing-discomfort-in-procedures-for-children-and-adults/21000/It may be useful to review some of the techniques and approaches used to minimize pain.Treatment Guidelines for the PicoWay® Laser System in Skin of Color
https://practicaldermatology.com/topics/general-topics/treatment-guidelines-for-the-picoway-laser-system-in-skin-of-color/22087/Picosecond laser therapy for benign pigmented lesionsThe Placebo and Nocebo Effects in Dermatology
https://practicaldermatology.com/columns/clinical-focus-1/the-placebo-and-nocebo-effects-in-dermatology/23559/Increasing evidence suggests that these effects—though not fully understood—may be harnessed for patient care.Tetracyclines: History and Current Formulation Review From a Dermatology Perspective
https://practicaldermatology.com/topics/general-topics/tetracyclines-history-and-current-formulation-review-from-a-dermatology-perspective/21233/'Clean Beauty' in Dermatology: A Scoping Review
https://practicaldermatology.com/issues/july-2025/clean-beauty/36492/The emergence of “clean beauty” as a consumer label has become a notable marketing trend, developed in the absence of standardized regulatory definitions, and it has been associated with shifts in consumer behaviors on a global scale.Atopic Dermatitis: A Review of Common Comorbidities
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-a-review-of-common-comorbidities/23352/It is important to acknowledge and identify comorbidities to successfully manage AD and improve patient quality of life.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.